Evolent Health (EVH) Stock Forecast & Price Target

Compare

746 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EVH Analyst Ratings

Strong Buy

13 Buy

0 Hold

0 Sell

Based on 13 analysts giving stock ratings to

Evolent

Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EVH Stock 12 Month Forecast

Average Price Target

$10.14

▲(161.34% Upside)

Based on 13 Wall Street analysts offering 12 month price targets for Evolent Health in the last 3 months. The average price target is $10.14 with a high forecast of $16.00 and a low forecast of $7.00. The average price target represents a 161.34% change from the last price of $3.88.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","10":"$10","17":"$17","6.5":"$6.5","13.5":"$13.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.14,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$10.14</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":7,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$7.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,6.5,10,13.5,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,4.923076923076923,5.846153846153847,6.769230769230769,7.6923076923076925,8.615384615384617,9.538461538461538,10.461538461538462,11.384615384615385,12.307692307692308,13.230769230769232,14.153846153846155,15.076923076923077,{"y":16,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,4.472307692307693,4.944615384615385,5.416923076923077,5.889230769230769,6.361538461538462,6.833846153846155,7.306153846153847,7.7784615384615385,8.250769230769231,8.723076923076924,9.195384615384615,9.66769230769231,{"y":10.14,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4,4.230769230769231,4.461538461538462,4.6923076923076925,4.923076923076923,5.153846153846154,5.384615384615385,5.615384615384615,5.846153846153847,6.076923076923077,6.307692307692308,6.538461538461538,6.769230769230769,{"y":7,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.71,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.25,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.45,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.99,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.68,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.95,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.57,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.63,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.98,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.61,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$16.00

Average Price Target$10.14

Lowest Price Target$7.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Richard Close

Canaccord Genuity

Buy

131.96%

Upside

Reiterated

11/25/25

Canaccord Genuity Keeps Their Buy Rating on Evolent Health (EVH)

Daniel Grosslight

Citi

$11.5→$9.5

Buy

144.85%

Upside

Reiterated

11/21/25

Evolent Health price target lowered to $9.50 from $11.50 at CitiEvolent Health price target lowered to $9.50 from $11.50 at Citi

Charles Rhyee

TD Cowen

Buy

106.19%

Upside

Reiterated

11/20/25

Evolent Health: Overly Pessimistic Valuation Presents a Buy Opportunity Amidst Exaggerated Concerns

John Stansel

J.P. Morgan

Buy

80.41%

Upside

Reiterated

11/14/25

J.P. Morgan Sticks to Their Buy Rating for Evolent Health (EVH)

David Larsen

BTIG

$16

Buy

312.37%

Upside

Reiterated

11/14/25

Evolent Health (EVH) Gets a Buy from BTIG

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/13/25

Evolent Health: Strong Growth Prospects and Strategic Market Positioning Justify Buy RatingWe are finalizing our Evolent Health model following third quarter 2025 earnings. Evolent reported a solid third quarter and continues to benefit from largely stable medical cost trend in 2025 (see our recap note for more details). For investors, however, all eyes have now turned to 2026, where current visibility to adjusted EBITDA is lower than would typically be the case —pending enrollment trends for key partners in both the ACA exchange and Medicare Advantage lines of business.

Jeffrey Garro

Stephens

Buy

80.41%

Upside

Upgraded

11/13/25

Evolent Health: Positioned for Growth with Strong Fundamentals and Valuation UpsideWe thought the print was enough for stabilization given already weak sentiment; however, fears over 2026 uncertainty weighed on shares. Subsequently, the government shutdown ending without a subsidy extension has confirmed what EVH was already baking into 2026 expectations.

Michael Wiederhorn

Oppenheimer

$18→$12

Buy

209.28%

Upside

Reiterated

11/12/25

Oppenheimer Remains a Buy on Evolent Health (EVH)

Sean Dodge

BMO Capital

Buy

80.41%

Upside

Initiated

11/12/25

BMO Capital's Optimistic Buy Rating for Evolent Health Driven by Strategic Stabilization and Growth Initiatives

Kevin Caliendo

UBS

$15→$10

Buy

157.73%

Upside

Reiterated

11/11/25

UBS Remains a Buy on Evolent Health (EVH)

Constantine Davides

Citizens JMP

$13→$11

Buy

183.51%

Upside

Reiterated

11/10/25

Evolent Health price target lowered to $11 from $13 at Citizens JMPEvolent Health price target lowered to $11 from $13 at Citizens JMP

Matthew Shea

Needham

$15

Buy

286.60%

Upside

Reiterated

11/07/25

Evolent Health's Strong Q3 Performance and Future Growth Potential Underpin Buy Recommendation

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

11/07/25

Analysts' Top Healthcare Picks: Evolent Health (EVH), CAMP4 Therapeutics Corporation (CAMP)

Jessica Tassan

Piper Sandler

$18

Buy

363.92%

Upside

Reiterated

09/05/25

Analysts Conflicted on These Healthcare Names: Novan (NASDAQ: NOVN), Lucid Diagnostics (NASDAQ: LUCD) and Evolent Health (NYSE: EVH)Reiterate OW following investor meetings with CFO John Johnson earlier this week. PT unchanged at $18.

Matthew Gillmor CFA

KeyBanc

$20

Buy

415.46%

Upside

Reiterated

08/20/25

KeyBanc Remains a Buy on Evolent Health (EVH)KeyBanc analyst Matthew Gillmor reiterated an Overweight rating and $20.00 price target on Evolent Health (NYSE: EVH).

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Richard Close

Canaccord Genuity

Buy

131.96%

Upside

Reiterated

11/25/25

Canaccord Genuity Keeps Their Buy Rating on Evolent Health (EVH)

Daniel Grosslight

Citi

$11.5→$9.5

Buy

144.85%

Upside

Reiterated

11/21/25

Evolent Health price target lowered to $9.50 from $11.50 at CitiEvolent Health price target lowered to $9.50 from $11.50 at Citi

Charles Rhyee

TD Cowen

Buy

106.19%

Upside

Reiterated

11/20/25

Evolent Health: Overly Pessimistic Valuation Presents a Buy Opportunity Amidst Exaggerated Concerns

John Stansel

J.P. Morgan

Buy

80.41%

Upside

Reiterated

11/14/25

J.P. Morgan Sticks to Their Buy Rating for Evolent Health (EVH)

David Larsen

BTIG

$16

Buy

312.37%

Upside

Reiterated

11/14/25

Evolent Health (EVH) Gets a Buy from BTIG

Ryan Daniels

William Blair

―

Buy

―

Reiterated

11/13/25

Jeffrey Garro

Stephens

Buy

80.41%

Upside

Upgraded

11/13/25

Michael Wiederhorn

Oppenheimer

$18→$12

Buy

209.28%

Upside

Reiterated

11/12/25

Oppenheimer Remains a Buy on Evolent Health (EVH)

Sean Dodge

BMO Capital

Buy

80.41%

Upside

Initiated

11/12/25

BMO Capital's Optimistic Buy Rating for Evolent Health Driven by Strategic Stabilization and Growth Initiatives

Kevin Caliendo

UBS

$15→$10

Buy

157.73%

Upside

Reiterated

11/11/25

UBS Remains a Buy on Evolent Health (EVH)

Constantine Davides

Citizens JMP

$13→$11

Buy

183.51%

Upside

Reiterated

11/10/25

Evolent Health price target lowered to $11 from $13 at Citizens JMPEvolent Health price target lowered to $11 from $13 at Citizens JMP

Matthew Shea

Needham

$15

Buy

286.60%

Upside

Reiterated

11/07/25

Evolent Health's Strong Q3 Performance and Future Growth Potential Underpin Buy Recommendation

Jailendra Singh

Truist Financial

―

Buy

―

Reiterated

11/07/25

Analysts' Top Healthcare Picks: Evolent Health (EVH), CAMP4 Therapeutics Corporation (CAMP)

Jessica Tassan

Piper Sandler

$18

Buy

363.92%

Upside

Reiterated

09/05/25

Matthew Gillmor CFA

KeyBanc

$20

Buy

415.46%

Upside

Reiterated

08/20/25

KeyBanc Remains a Buy on Evolent Health (EVH)KeyBanc analyst Matthew Gillmor reiterated an Overweight rating and $20.00 price target on Evolent Health (NYSE: EVH).

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Evolent Health

1 Month

xxx

Success Rate

25/48 ratings generated profit

Average Return

+0.27%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 52.08% of your transactions generating a profit, with an average return of +0.27% per trade.

3 Months

xxx

Success Rate

24/48 ratings generated profit

Average Return

-0.10%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of -0.10% per trade.

1 Year

Richard CloseCanaccord Genuity

Success Rate

20/48 ratings generated profit

Average Return

+6.34%

reiterated a buy rating 17 days ago

Copying Richard Close's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +6.34% per trade.

2 Years

xxx

Success Rate

17/48 ratings generated profit

Average Return

+10.95%

reiterated a xxx

rating 17 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 35.42% of your transactions generating a profit, with an average return of +10.95% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EVH Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EVH has received 19 Buy Ratings, 7 Hold Ratings, and 1 Sell Ratings. EVH average Analyst price target in the past 3 months is 10.14.

Each month's total comprises the sum of three months' worth of ratings.

EVH Financial Forecast

EVH Earnings Forecast

Next quarter’s earnings estimate for EVH is $0.05 with a range of -$0.05 to $0.09. The previous quarter’s EPS was $0.05. EVH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year EVH has Performed in-line its overall industry.

EVH Sales Forecast

Next quarter’s sales forecast for EVH is $469.67M with a range of $461.93M to $484.10M. The previous quarter’s sales results were $479.53M. EVH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year EVH has Performed in-line its overall industry.

EVH Stock Forecast FAQ

What is EVH’s average 12-month price target, according to analysts?

Based on analyst ratings, Evolent Health’s 12-month average price target is 10.14.

What is EVH’s upside potential, based on the analysts’ average price target?

Evolent Health has 161.34% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EVH a Buy, Sell or Hold?

Evolent Health has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.

What is Evolent Health’s price target?

The average price target for Evolent Health is 10.14. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $16.00 ,the lowest forecast is $7.00. The average price target represents 161.34% Increase from the current price of $3.88.

What do analysts say about Evolent Health?

Evolent Health’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.

How can I buy shares of EVH?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Evolent Health (EVH) Stock Forecast & Price Target

EVH Analyst Ratings

EVH Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Evolent Health

EVH Analyst Recommendation Trends

EVH Financial Forecast

EVH Earnings Forecast

EVH Sales Forecast

EVH Stock Forecast FAQ

Detailed List of Analyst Forecasts